retatrutide dementia Can be used to treat or promote weight loss in an older adult with dementia and obesity? Unrecognizable in 2 Months: Retatrutide

are obese, with BMIs of 30 and higher

Retatrutide targets three hormone receptors simultaneously (GLP-1, GIP, and glucagon), distinguishing it from approved agents such as semaglutide (GLP-1 agonist) and tirzepatide (dual GIP/GLP-1 agonist)

Our patches come with a clearbackingdesigned specifically to make sure every patch is usable, every time

Tirzepatide (approved GIP/GLP-1 agonist) achieves 15-22% weight loss

Because of this, retatrutide is often discussed as a next-generation option rather than a currently accessible treatment

Older adults or those with reduced physiological reserve may benefit from a more cautious escalation approach